Topics to include:

• Increased scrutiny of 340B program from Congress and government agencies.
• Implications of Government Accountability Office report for providers, industry and HRSA.
• Upcoming audits from the government and drug manufacturers.
• Growing use of contract pharmacies and how to implement win-win partnerships.
• A closer look how a user fee to fund 340B government operations would work.
• Third party reimbursement trends and efforts by providers to challenge these contracts.
• Implications of reductions in Medicaid reimbursement to 340B providers and efforts to design mutually beneficial arrangements.
• Status of 340B legislation including extending 340B pricing to inpatient setting,  repeal of orphan drug discount restriction and exemption from 340B pricing on drugs in short supply.
• Regulation defining scope of orphan drug discount restriction.
• Possible congressional hearings on 340B program.
• New guidance from HRSA when drug prices drop to a penny.

There will also be two half-day pre-conference workshops to choose from (1) an introduction to the 340B program and (2) implementing contract pharmacy arrangements and ensuring compliance.